

Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia

Melchior Lauten,¹ Anja Möricke,² Rita Beier,³ Martin Zimmermann,³ Martin Stanulla,² Barbara Meissner,² Edelgard Odenwald,³ Andishe Attarbaschi,⁴ Charlotte Niemeyer,⁵ Felix Niggli,⁶ Hansjörg Riehm,³ and Martin Schrappe²

¹Pediatric Hematology and Oncology, University Hospital Schleswig-Holstein, Lübeck Campus, Germany; ²Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel Campus, Germany; ³Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; ⁴St. Anna Children's Hospital, Vienna, Austria; ⁵Pediatric Hematology and Oncology, University Hospital Freiburg, Germany; and ⁶Kinderspital, University Hospital Zürich, Switzerland

Citation: Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, and Schrappe M. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. *Haematologica* 2012;97(7):1048-1056.

doi:10.3324/haematol.2011.047613

Online Supplementary Table S1. Characteristics of all patients of the ALL-BFM 95 trial.

Variable	Patients not included		Patients included N ¹ (%)	P ²
	Patients with missing information on BM Day 15 N ¹ (%)	Patients with unrepresentative BM Day 15 N ¹ (%)		
All	437 (100)	265 (100)	1437 (100)	
Gender				
Male	276 (58.4)	129 (48.7)	821 (57.4)	0.27
Female	197 (41.6)	136 (51.3)	610 (42.6)	
Age at diagnosis (years)				
<1 ³	4 (1.5)	4 (1.5)	26 (1.8)	0.103
1 - <6	277 (58.6)	170 (64.2)	808 (56.5)	
6 - <10	102 (21.6)	51 (19.2)	294 (20.5)	
≥10	90 (19.0)	40 (15.1)	303 (21.2)	
Initial WBC (x10 ⁹ /L)				
<20	319 (67.4)	179 (67.5)	892 (62.3)	0.010
20 - <50	76 (16.1)	50 (18.9)	236 (16.5)	
50 - <100	33 (7.0)	21 (7.9)	126 (8.8)	
≥100	45 (9.5)	15 (5.7)	177 (12.4)	
Immunophenotype				
T-ALL	69 (15.9)	14 (5.6)	194 (14.0)	0.25
pB-ALL	364 (84.1)	238 (94.4)	1196 (86.0)	
CNS involvement				
Negative	421 (89.4)	227 (86.0)	1300 (91.2)	0.059
TLP+ ⁴	33 (7.0)	30 (11.4)	85 (6.0)	
Positive	17 (3.6)	7 (2.7)	40 (2.8)	
TEL/AML1				
Positive	219 (78.5)	139 (80.3)	558 (78.2)	0.67
Negative	60 (21.5)	34 (19.7)	156 (21.8)	
BCR/ABL				
Positive	418 (98.8)	238 (98.8)	1262 (97.4)	0.040
Negative	5 (1.2)	3 (1.2)	34 (2.6)	
Risk group (ALL-BFM 95) ⁵				
Standard	175 (37.0)	109 (41.1)	474 (33.1)	<0.001
Intermediate	258 (54.5)	139 (52.5)	760 (53.1)	
High	40 (8.5)	17 (6.4)	197 (13.8)	
Prednisone response				
Good	433 (92.9)	250 (95.4)	1280 (90.2)	0.005
Poor	33 (7.1)	12 (4.6)	139 (9.8)	
Remission Day 33				
No	6 (1.3)	1 (0.4)	42 (3.0)	0.004
Yes	448 (98.7)	258 (99.6)	1373 (97.0)	

¹Data given refer to patients with successful investigation of the respective criterion. ²The P value (χ^2 test) refers to the comparison of patients included vs. not included. ³Patients treated according to the Interfant-99 pilot study were excluded. ⁴TLP+ indicates traumatic lumbar puncture with evidence of leukemic blasts in cerebral spinal fluid. ⁵According to the risk criteria of trial ALL-BFM 95.